Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.51 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27786896 | 0.91 | PTPN1 (0.47) | ALDH1A1ADRB2ADRB1ADRB3LMNA | |
| SCHEMBL9935576 | 0.90 | ALDH1A1 (0.59) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL18651713 | 0.87 | ALDH1A1 (0.59) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL3181495 | 0.85 | ALDH1A1 (0.61) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL29964300 | 0.85 | ALDH1A1 (0.61) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| Ethylene SCHEMBL19616645 | 0.82 | ALDH1A1 (0.57) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL784821 | 0.81 | ALDH1A1 (0.65) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| Propene SCHEMBL1270277 | 0.80 | PRKCA (0.52) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL21869784 | 0.80 | ALDH1A1 (0.55) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL17429724 | 0.79 | ALDH1A1 (0.62) | ALDH1A1ADRB2ADRB1ADRB3PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10449258-B2 | Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2019-10-22 | — | — | US | disclosed |
| US-20180161446-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2018-06-14 | — | — | US | disclosed |
| US-20180161446-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2018-06-14 | — | — | US | disclosed |
| EP-3308801-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | XDCExplorer (Shanghai) Co., Ltd. (CN) | 2018-04-18 | — | — | EP | disclosed |
| US-5025005-A | Preventive or therapeutic agents for circulatory diseases, allergic disorders; antineoplastic agent; inhibitor for platelet activating factor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-06-18 | — | — | US | disclosed |
| US-4737518-A | ANTIALLERGENS, ANTINEOPLASTICS, ANTICOAGULANTS, CIRCULATORY DISEASES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-04-12 | — | — | US | disclosed |
| EP-0157609-A2 | Lipid derivatives their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10449258-B2 | Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof | FCGR3B, SI, INCENP | ALDH1A1 567/4885ADRB2 2851/4885ADRB1 2458/4885 |
| US-20180161446-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | FCGR3B, SI, INCENP | ALDH1A1 567/4885ADRB2 2851/4885ADRB1 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.